Amrutanjan Health Care Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 7:30 am

Competitors of Amrutanjan Health Care Ltd

All Competitor Stocks of Amrutanjan Health Care Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:50 pm

Below is a detailed analysis of the quarterly data for Amrutanjan Health Care Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 94.05 Cr.. The value appears to be declining and may need further review. It has decreased from 135.41 Cr. (Mar 2025) to 94.05 Cr., marking a decrease of 41.36 Cr..
• For Expenses, as of Jun 2025, the value is 85.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 117.71 Cr. (Mar 2025) to 85.61 Cr., marking a decrease of 32.10 Cr..
• For Operating Profit, as of Jun 2025, the value is 8.44 Cr.. The value appears to be declining and may need further review. It has decreased from 17.70 Cr. (Mar 2025) to 8.44 Cr., marking a decrease of 9.26 Cr..
• For OPM %, as of Jun 2025, the value is 8.97%. The value appears to be declining and may need further review. It has decreased from 13.07% (Mar 2025) to 8.97%, marking a decrease of 4.10%.
• For Other Income, as of Jun 2025, the value is 4.43 Cr.. The value appears to be declining and may need further review. It has decreased from 4.82 Cr. (Mar 2025) to 4.43 Cr., marking a decrease of 0.39 Cr..
• For Interest, as of Jun 2025, the value is 0.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.04 Cr. (Mar 2025) to 0.05 Cr., marking an increase of 0.01 Cr..
• For Depreciation, as of Jun 2025, the value is 1.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.62 Cr. (Mar 2025) to 1.53 Cr., marking a decrease of 0.09 Cr..
• For Profit before tax, as of Jun 2025, the value is 11.29 Cr.. The value appears to be declining and may need further review. It has decreased from 20.86 Cr. (Mar 2025) to 11.29 Cr., marking a decrease of 9.57 Cr..
• For Tax %, as of Jun 2025, the value is 26.40%. The value appears to be improving (decreasing) as expected. It has decreased from 27.23% (Mar 2025) to 26.40%, marking a decrease of 0.83%.
• For Net Profit, as of Jun 2025, the value is 8.31 Cr.. The value appears to be declining and may need further review. It has decreased from 15.18 Cr. (Mar 2025) to 8.31 Cr., marking a decrease of 6.87 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.87. The value appears to be declining and may need further review. It has decreased from 5.25 (Mar 2025) to 2.87, marking a decrease of 2.38.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:47 am

Growth

Last Updated: September 4, 2025, 11:10 pm

Balance Sheet

Last Updated: June 16, 2025, 12:30 pm

Below is a detailed analysis of the balance sheet data for Amrutanjan Health Care Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
• For Reserves, as of Mar 2025, the value is 324.00 Cr.. The value appears strong and on an upward trend. It has increased from 286.00 Cr. (Mar 2024) to 324.00 Cr., marking an increase of 38.00 Cr..
• For Borrowings, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 93.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 77.00 Cr. (Mar 2024) to 93.00 Cr., marking an increase of 16.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 421.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 367.00 Cr. (Mar 2024) to 421.00 Cr., marking an increase of 54.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2024) to 49.00 Cr., marking a decrease of 1.00 Cr..
• For CWIP, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 14.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 356.00 Cr.. The value appears strong and on an upward trend. It has increased from 315.00 Cr. (Mar 2024) to 356.00 Cr., marking an increase of 41.00 Cr..
• For Total Assets, as of Mar 2025, the value is 421.00 Cr.. The value appears strong and on an upward trend. It has increased from 367.00 Cr. (Mar 2024) to 421.00 Cr., marking an increase of 54.00 Cr..

Notably, the Reserves (324.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Amrutanjan Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 17, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 16) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
• For Diluted EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
• For Cash EPS (Rs.), as of Mar 17, the value is 16.43. This value is within the healthy range. It has increased from 16.37 (Mar 16) to 16.43, marking an increase of 0.06.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
• For Revenue From Operations / Share (Rs.), as of Mar 17, the value is 153.25. It has increased from 127.77 (Mar 16) to 153.25, marking an increase of 25.48.
• For PBDIT / Share (Rs.), as of Mar 17, the value is 23.16. This value is within the healthy range. It has decreased from 24.95 (Mar 16) to 23.16, marking a decrease of 1.79.
• For PBIT / Share (Rs.), as of Mar 17, the value is 21.20. This value is within the healthy range. It has decreased from 22.66 (Mar 16) to 21.20, marking a decrease of 1.46.
• For PBT / Share (Rs.), as of Mar 17, the value is 22.75. This value is within the healthy range. It has increased from 22.36 (Mar 16) to 22.75, marking an increase of 0.39.
• For Net Profit / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
• For NP After MI And SOA / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
• For PBDIT Margin (%), as of Mar 17, the value is 15.11. This value is within the healthy range. It has decreased from 19.52 (Mar 16) to 15.11, marking a decrease of 4.41.
• For PBIT Margin (%), as of Mar 17, the value is 13.83. This value is within the healthy range. It has decreased from 17.73 (Mar 16) to 13.83, marking a decrease of 3.90.
• For PBT Margin (%), as of Mar 17, the value is 14.84. This value is within the healthy range. It has decreased from 17.50 (Mar 16) to 14.84, marking a decrease of 2.66.
• For Net Profit Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
• For NP After MI And SOA Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
• For Return on Networth / Equity (%), as of Mar 17, the value is 16.77. This value is within the healthy range. It has decreased from 18.92 (Mar 16) to 16.77, marking a decrease of 2.15.
• For Return on Capital Employeed (%), as of Mar 17, the value is 23.87. This value is within the healthy range. It has decreased from 29.45 (Mar 16) to 23.87, marking a decrease of 5.58.
• For Return On Assets (%), as of Mar 17, the value is 13.07. This value is within the healthy range. It has decreased from 14.65 (Mar 16) to 13.07, marking a decrease of 1.58.
• For Total Debt / Equity (X), as of Mar 17, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 16) to 0.01, marking a decrease of 0.01.
• For Asset Turnover Ratio (%), as of Mar 17, the value is 1.48. It has increased from 1.35 (Mar 16) to 1.48, marking an increase of 0.13.
• For Current Ratio (X), as of Mar 17, the value is 3.46. This value exceeds the healthy maximum of 3. It has decreased from 3.59 (Mar 16) to 3.46, marking a decrease of 0.13.
• For Quick Ratio (X), as of Mar 17, the value is 3.15. This value exceeds the healthy maximum of 2. It has decreased from 3.27 (Mar 16) to 3.15, marking a decrease of 0.12.
• For Inventory Turnover Ratio (X), as of Mar 17, the value is 7.67. This value is within the healthy range. It has increased from 7.09 (Mar 16) to 7.67, marking an increase of 0.58.
• For Dividend Payout Ratio (NP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 27.34 (Mar 16) to 0.00, marking a decrease of 27.34.
• For Dividend Payout Ratio (CP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 23.52 (Mar 16) to 0.00, marking a decrease of 23.52.
• For Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 72.66 (Mar 16) to 0.00, marking a decrease of 72.66.
• For Cash Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 76.48 (Mar 16) to 0.00, marking a decrease of 76.48.
• For Interest Coverage Ratio (X), as of Mar 17, the value is 78.72. This value is within the healthy range. It has decreased from 83.47 (Mar 16) to 78.72, marking a decrease of 4.75.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 17, the value is 43.91. This value is within the healthy range. It has decreased from 48.10 (Mar 16) to 43.91, marking a decrease of 4.19.
• For Enterprise Value (Cr.), as of Mar 17, the value is 817.64. It has increased from 564.15 (Mar 16) to 817.64, marking an increase of 253.49.
• For EV / Net Operating Revenue (X), as of Mar 17, the value is 3.65. This value exceeds the healthy maximum of 3. It has increased from 3.02 (Mar 16) to 3.65, marking an increase of 0.63.
• For EV / EBITDA (X), as of Mar 17, the value is 24.16. This value exceeds the healthy maximum of 15. It has increased from 15.47 (Mar 16) to 24.16, marking an increase of 8.69.
• For MarketCap / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
• For Retention Ratios (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 72.65 (Mar 16) to 0.00, marking a decrease of 72.65.
• For Price / BV (X), as of Mar 17, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 5.61 (Mar 16) to 6.85, marking an increase of 1.24.
• For Price / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
• For EarningsYield, as of Mar 17, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 16) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness